Blood Cholesterol Testing - don't let the routine standard lipid panel fool you!
The traditional cholesterol test - standard lipid panel
The Advanced Lipid Panel - next generation cholesterol testing
What to look for in your Advanced Lipid Test results?
Advanced Lipid Panel Labs
Who should get the advanced lipid panel test?
1. Castelli, W.P., et al., Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol, 1992. 2(1-2): p. 23-8.
2. Brown, M.S. and J.L. Goldstein, A receptor-mediated pathway for cholesterol homeostasis. Science, 1986. 232(4746): p. 34-47.
3. Castelli, W.P. and K. Anderson, A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med, 1986. 80(2A): p. 23-32.
4. Martin, S.S., et al., Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol, 2013. 62(8): p. 732-9.
5. Mora, S., et al., Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem, 2009. 55(5): p. 888-94.
6. Superko, H.R., Did grandma give you heart disease? The new battle against coronary artery disease. Am J Cardiol, 1998. 82(9A): p. 34Q-46Q.
7. Freedman, D.S., et al., The relation of documented coronary artery disease to levels of total cholesterol and high-density lipoprotein cholesterol. Epidemiology, 1994. 5(1): p. 80-7.
8. Grover, S.A., L. Coupal, and X.P. Hu, Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA, 1995. 274(10): p. 801-6.
9. Packard, C.J. and J. Shepherd, Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol, 1997. 17(12): p. 3542-56.
10. Cromwell, W.C., et al., LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidol, 2007. 1(6): p. 583-92.
11. Austin, M.A., et al., Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA, 1988. 260(13): p. 1917-21.
12. Lamarche, B., I. Lemieux, and J.P. Despres, The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab, 1999. 25(3): p. 199-211.
13. Williams, P.T., et al., Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease. Atherosclerosis, 2014. 233(2): p. 713-20.
14. Chandra, A. and A. Rohatgi, The role of advanced lipid testing in the prediction of cardiovascular disease. Curr Atheroscler Rep, 2014. 16(3): p. 394.
15. Berneis, K.K. and R.M. Krauss, Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res, 2002. 43(9): p. 1363-79.
16. Krauss, R.M. and P.W. Siri, Metabolic abnormalities: triglyceride and low-density lipoprotein. Endocrinol Metab Clin North Am, 2004. 33(2): p. 405-15.
17. Ip, S., et al., Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med, 2009. 150(7): p. 474-84.
18. Krauss, R.M., Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol, 2010. 21(4): p. 305-11.
19. Davidson, M.H., et al., Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol, 2011. 5(5): p. 338-67.
20. Cromwell, W.C. and J.D. Otvos, Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol, 2006. 98(12): p. 1599-602.
21. Otvos, J.D., E.J. Jeyarajah, and W.C. Cromwell, Measurement issues related to lipoprotein heterogeneity. Am J Cardiol, 2002. 90(8A): p. 22i-29i.
22. Mora, S., J.E. Buring, and P.M. Ridker, Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation, 2014. 129(5): p. 553-61.
23. Mora, S., et al., Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation, 2009. 119(7): p. 931-9.
24. Otvos, J.D., et al., Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol, 2011. 5(2): p. 105-13.
25. Blake, G.J., et al., Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation, 2002. 106(15): p. 1930-7.
26. El Harchaoui, K., et al., Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol, 2007. 49(5): p. 547-53.
27. Connelly, M.A., I. Shalaurova, and J.D. Otvos, High-density lipoprotein and inflammation in cardiovascular disease. Transl Res, 2016.
28. Kontush, A., HDL particle number and size as predictors of cardiovascular disease. Front Pharmacol, 2015. 6: p. 218.
29. El Harchaoui, K., et al., High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med, 2009. 150(2): p. 84-93.
30. Mackey, R.H., et al., High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol, 2012. 60(6): p. 508-16.
31. Feingold, K.R. and C. Grunfeld, Introduction to Lipids and Lipoproteins, in Endotext, L.J. De Groot, et al., Editors. 2000: South Dartmouth (MA).
32. Superko, H.R., Advanced lipoprotein testing and subfractionation are clinically useful. Circulation, 2009. 119(17): p. 2383-95.
33. Nordestgaard, B.G., et al., Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J, 2010. 31(23): p. 2844-53.
34. Jacobson, T.A., Lipoprotein(a), cardiovascular disease, and contemporary management. Mayo Clin Proc, 2013. 88(11): p. 1294-311.
35. Kassner, U., et al., Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler Suppl, 2015. 18: p. 263-7.
36. Mora, S., Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. Circulation, 2009. 119(17): p. 2396-404.
37. Kuller, L., et al., Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol, 2002. 22(7): p. 1175-80.
38. Schaefer, E.J., et al., The Measurement of Lipids, Lipoproteins, Apolipoproteins, Fatty Acids, and Sterols, and Next Generation Sequencing for the Diagnosis and Treatment of Lipid Disorders, in Endotext, L.J. De Groot, et al., Editors. 2000: South Dartmouth (MA).
39. Shalaurova, I., et al., Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab Syndr Relat Disord, 2014. 12(8): p. 422-9.
40. Grundy, S.M., et al., Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial). Am J Cardiol, 2011. 108(1): p. 40-6.
41. McLaughlin, T., et al., Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol, 2005. 96(3): p. 399-404.
42. Sniderman, A.D., Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. J Clin Lipidol, 2008. 2(1): p. 36-42.
43. Rosenson, R.S. and J.A. Underberg, Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Cardiovasc Drugs Ther, 2013. 27(5): p. 465-79.
44. Faghihnia, N., et al., Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J Lipid Res, 2010. 51(11): p. 3324-30.
45. Krauss, R.M., Dietary and genetic probes of atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol, 2005. 25(11): p. 2265-72.
46. Dreon, D.M., et al., Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB J, 1994. 8(1): p. 121-6.
47. Parks, E.J. and M.K. Hellerstein, Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr, 2000. 71(2): p. 412-33.
48. Kasim-Karakas, S.E., et al., Effects of dietary fat restriction on particle size of plasma lipoproteins in postmenopausal women. Metabolism, 1997. 46(4): p. 431-6.
49. Maki, K.C., et al., Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr, 2005. 24(3): p. 189-99.
50. Neff, L.M., et al., Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. J Nutr, 2011. 141(2): p. 207-13.